NEWS: 公告在东京证券交易所JASDAQ标准市场新上市



Gonorrhea Therapeutics Market - Growth, Trends, and Forecasts (2020 - 2025)

出版商 Mordor Intelligence Pvt Ltd 商品编码 921972
出版日期 内容资讯 英文 110 Pages
商品交期: 2-3个工作天内
全球淋病治疗市场:成长,趋势,及预测 Gonorrhea Therapeutics Market - Growth, Trends, and Forecasts (2020 - 2025)
出版日期: 2020年06月01日内容资讯: 英文 110 Pages



第1章 简介

  • 调查成果
  • 调查的前提条件
  • 调查范围

第2章 调查方法

第3章 摘要整理

第4章 市场动态

  • 市场概况
  • 市场成长要素
    • 淋病负担增加
    • 政府及民间部门在全国宣传活动的参加度扩大
  • 市场阻碍因素
    • 严格的法规方案
    • 与性病门诊患者相关的社会污名
  • 波特的五力分析

第5章 市场区隔

  • 各淋菌感染
    • 单纯性淋球菌感染
    • 淋菌性关节炎
    • 淋菌性脑膜炎及心内膜炎
  • 不同治疗
    • 单一疗法
    • 双重疗法
  • 各终端用户
    • 医院药局
    • 零售药局
    • 线上药局
  • 各地区
    • 北美
    • 欧洲
    • 亚太地区
    • 中东·非洲
    • 南美

第6章 竞争情形

  • 企业简介
    • Allergan, Inc.
    • F. Hoffmann-La Roche Ltd
    • GlaxoSmithKline plc
    • Lupin Pharmaceuticals
    • Pfizer Inc.
    • Teligent, Inc.

第7章 市场机会及今后趋势


Product Code: 67485

Gonorrhea is an infection caused by a sexually transmitted bacterium that infects both males and females. The primary factors such as the rising prevalence of gonorrhea, implementation of national screening programs and growing public awareness are propelling the growth of the gonorrhea therapeutics market. According to the Centers for Disease Control and Prevention (CDC), around 700,000 new cases of gonorrhea are detected each year. In 2019, the National Institute of Allergy and Infectious Diseases (NIAID) has granted USD 41.6 million over five years to support collaborative, multidisciplinary research on the bacteria that cause syphilis, gonorrhea, and chlamydia. Thus, with the growing prevalence of STDs increases patient awareness through national campaigns and growing government initiatives are anticipated to drive market growth.

However, stringent regulatory scenarios and social stigma associated with patients visiting STD clinics are expected to restrain the growth of the global market in the forecast period.

Key Market Trends

Dual Therapy Segment is Expected to Register Good Growth Over the Forecast Period

By Treatment, the market has been segmented into monotherapy and dual therapy. Gonorrhea, caused by Neisseria gonorrhoeae, is the second most common bacterial STI and results in substantial morbidity. The dual therapy segment is estimated to dominate the global market, and this trend is expected to continue over the forecast period. Dual therapy with ceftriaxone and azithromycin is recommended as the first-line regimen for the treatment of gonorrhea. WHO recommends dual therapy over monotherapy for people with symptomatic and asymptomatic gonorrhea. Also, monotherapy is no longer a viable option in many settings worldwide. In addition, growing public awareness and a large patient pool also contribute to the growth of the gonorrhea therapeutics market.

North America is Estimated to Lead the Gonorrhea Therapeutics Market

North America is expected to lead the market, owing to high standards of healthcare infrastructure and easy availability of sophisticated technology in this region. As per CDC estimates, in 2018 around 583,405 cases of gonorrhea were reported in the United States. However, Europe and the Asia Pacific are followed next after North America owing to the increasing incidence of gonococcal infection, and the rise in collaboration of domestic and international companies in these regions. For instance, In 2019, Binx health announced that its proprietary Chlamydia and Gonorrhea (CT/NG) test has received European CE Mark approval, which is expected to drive the gonorrhea therapeutics market in the forecast period.

Competitive Landscape

The market for gonorrhea therapeutics is consolidated in terms of competition with a presence of few major pharmaceutical companies. Some of the major players in the gonorrhea therapeutics market includes Allergan, Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Lupin Pharmaceuticals, Pfizer Inc, Teligent, Inc., among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents


  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Gonorrhea
    • 4.2.2 Growing Government and Private Sector Participation Through National Campaigns
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Scenario
    • 4.3.2 Social Stigma Associated With Patients Visiting STD Clinics
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Gonococcal Infection
    • 5.1.1 Uncomplicated Gonococcal Infection
    • 5.1.2 Gonococcal Arthritis
    • 5.1.3 Gonococcal Meningitis and Endocarditis
  • 5.2 By Treatment
    • 5.2.1 Monotherapy
    • 5.2.2 Dual Therapy
  • 5.3 By End User
    • 5.3.1 Hospital Pharmacies
    • 5.3.2 Retail Pharmacies
    • 5.3.3 Online Pharmacies
  • 5.4 Geography
    • 5.4.1 North America
      • United States
      • Canada
      • Mexico
    • 5.4.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.4.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.4.4 Middle-East & Africa
      • GCC
      • South Africa
      • Rest of Middle-East and Africa
    • 5.4.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Allergan, Inc.
    • 6.1.2 F. Hoffmann-La Roche Ltd
    • 6.1.3 GlaxoSmithKline plc
    • 6.1.4 Lupin Pharmaceuticals
    • 6.1.5 Pfizer Inc.
    • 6.1.6 Teligent, Inc.